Petrelintide
Sources
registry, as of 2026-11-05
https://clinicaltrials.gov/study/NCT07843485
Protocol section, NCT07843485 ZUPREME-4, last update posted 2026-11-05
registry, as of 2026-11-05
https://clinicaltrials.gov/study/NCT07843498
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 3900. Conditions Obesity or Overweight. This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity, at least one weight-related comorbidity, an
ClinicalTrials.gov NCT07843498 protocol and results modules
registry, as of 2026-10-07Stale
https://clinicaltrials.gov/study/NCT07843472
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease. Overall status RECRUITING. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 2500. Conditions Obesity or Overweight; Cardiovascular Disease. This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD)
ClinicalTrials.gov NCT07843472 protocol and results modules
registry, as of 2026-03-23Stale
https://clinicaltrials.gov/study/NCT06662539
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities. Overall status COMPLETED. Phases PHASE2. Lead sponsor Zealand Pharma. Enrollment 493. Conditions Obesity. The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.
ClinicalTrials.gov NCT06662539 protocol and results modules
registry, as of 2026-09-09Stale
https://clinicaltrials.gov/study/NCT06926842
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2). Overall status COMPLETED. Phases PHASE2. Lead sponsor Zealand Pharma. Enrollment 221. Conditions Overweight; Type 2 Diabetes; Obesity. The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
ClinicalTrials.gov NCT06926842 protocol and results modules
registry, as of 2026-04-08Stale
https://clinicaltrials.gov/study/NCT07338214
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations. Overall status COMPLETED. Phases PHASE1. Lead sponsor Zealand Pharma. Enrollment 48. Conditions Obesity & Overweight. This clinical research study is testing the study compound petrelintide that is being developed for the weight management in people with obesity or overweight with co-morbidities or related diseases. The goal is to learn how the same single dose of petrelintide, given using diff
ClinicalTrials.gov NCT07338214 protocol and results modules
publication, as of 2025-11-27Stale
https://pubmed.ncbi.nlm.nih.gov/41217931/
Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. The past few years have seen the approval of several medications for weight management, but there is an increasing need for new therapies that target different pathways of energy
PMID 41217931